Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Tax Reform Requests Cover Support for MCM Preparedness
The Ministry of Health, Labor and Welfare (MHLW) on August 26 unveiled its tax reform requests for FY2027, including potential measures tied to government efforts to bolster infectious disease preparedness with medical countermeasures (MCMs). The government plans to enhance and…
To read the full story
Related Article
- MHLW Seeks Record 36.6 Trillion Yen for FY2027, Puts AI in Focus
August 27, 2026
- Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
March 25, 2026
- Deduction Formula for IP Box Tax Relief Now Clear as Preparations Move Ahead
February 22, 2024
- MHLW Announces “Innovation Box” Tax Regime: FY2024 Reform
December 25, 2023
- Japan OKs FY2024 Tax Reform Outline, “Innovation Box” Scheme Etched
December 15, 2023
REGULATORY
- PMDA Generic GMP Inspections a Real-World Test to Stem Startup Risks: Official
September 8, 2026
- CEA Review Finds Past Decisions Sound, Sees Room for More Transparency
September 8, 2026
- MHLW Adds Pomalyst Generics to RevMate Safety Program
September 8, 2026
- Japan Extends Shelf Life of Stockpiled Xofluza to 9 Years
September 8, 2026
- MHLW Seeks at Least 275 Billion Yen to Shore Up Drug Supplies
September 7, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…